Novavax (NASDAQ:NVAX) Stock Moved Up to Buy by Wall Street Zen

Novavax (NASDAQ:NVAX) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other analysts also recently commented on NVAX. Citigroup reissued a “sell” rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Novavax in a research note on Monday. B. Riley Financial reissued a “buy” rating and set a $16.00 target price (down from $18.00) on shares of Novavax in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Novavax in a research note on Tuesday, October 27th. Finally, Zacks Research cut Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $12.33.

Novavax Price Performance

NVAX opened at $10.78 on Friday. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -23.43 and a beta of 2.65. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $13.39. The company’s 50 day moving average price is $10.56 and its two-hundred day moving average price is $9.35.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.16. The firm had revenue of $68.30 million for the quarter, compared to the consensus estimate of $50.42 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The company’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.25) earnings per share. As a group, equities research analysts predict that Novavax will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in NVAX. Russell Investments Group Ltd. raised its position in shares of Novavax by 5.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 94,969 shares of the biopharmaceutical company’s stock valued at $1,027,000 after buying an additional 4,632 shares during the period. Fulcrum Asset Management LLP acquired a new stake in shares of Novavax during the 3rd quarter valued at $181,000. Allspring Global Investments Holdings LLC grew its stake in Novavax by 4.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 27,820 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 1,207 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Novavax during the third quarter valued at approximately $91,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Novavax by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 30,096 shares of the biopharmaceutical company’s stock valued at $326,000 after acquiring an additional 3,926 shares during the period. Institutional investors own 53.04% of the company’s stock.

Key Stories Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.